Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

被引:161
作者
Cedres, Susana [1 ]
Ponce-Aix, Santiago [2 ]
Zugazagoitia, Jon [2 ]
Sansano, Irene [3 ]
Enguita, Ana [4 ]
Navarro-Mendivil, Alejandro [1 ]
Martinez-Marti, Alex [1 ]
Martinez, Pablo [1 ]
Felip, Enriqueta [1 ]
机构
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Med Oncol Serv, Barcelona, Spain
[2] 12 Octubre Univ Hosp, Med Oncol Serv, Madrid, Spain
[3] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain
[4] 12 Octubre Univ Hosp, Dept Pathol, Madrid, Spain
关键词
B7-H1; EXPRESSION; EXTRAPLEURAL PNEUMONECTOMY; INDUCTION CHEMOTHERAPY; SPONTANEOUS REGRESSION; T-CELLS; SURVIVAL; ANTIBODY; SAFETY; INFILTRATION; LYMPHOCYTES;
D O I
10.1371/journal.pone.0121071
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The increasing incidence and poor outcome associated with MPM requires finding effective treatment for this disease. PD1/PD-L1 pathway plays a central role in tumor immune evasion and appears to be predictive and prognostic marker. PD-L1 is expressed in many different human cancers but its role in MPM has yet to be established. The aim of this study is to evaluate the expression of PD-L1 in MPM. Methods 119 MPM patients (p) from two institutions between November 2002 and February 2014 were reviewed. Formalin-fixed, paraffin-embedded tissue was stained with anti-PD-L1 (clone E1L3N). Cases showing more than 1% of tumor cells expression of PD-L1 were considered positive. Results PD-L1 was analyzed in 77 p with tumor tissue available and was positive in 20.7% p (14 samples in membrane, 16 in cytoplasm and 4 in immune infiltrate). PD-L1 intensity was weak in 56.2%, moderate in 25% and strong in 18.7% p. There was a significant relationship between PD-L1 expression and histology (PD-L1 expression 37.5% in no-epithelioid tumor and 13.2% in epithelioid; p=0.033). The median survival in p PD-L1 positive was 4.79 vs 16.3 months in p PD-L1 negative (p=0.012). Conclusions We have shown PD-L1 is expressed in 20% of patients, associated with no epithelioid histology and poor prognostic in MPM. Our results suggest PD-L1 warrants further exploration in selecting p for immunotherapy.
引用
收藏
页数:12
相关论文
共 46 条
[1]   Apparent spontaneous complete regression of a multifocal malignant mesothelioma of the pleura [J].
Allen, Roger K. A. .
MEDICAL JOURNAL OF AUSTRALIA, 2007, 187 (07) :413-415
[2]  
[Anonymous], [No title captured]
[3]  
[Anonymous], 2009, TNM classification of malignant tumors, V7th edn
[4]   Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma [J].
Anraku, Masaki ;
Cunningham, Kristopher S. ;
Yun, Zhihong ;
Tsao, Ming-Sound ;
Zhang, Li ;
Keshavjee, Shaf ;
Johnston, Michael R. ;
de Perrot, Marc .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 135 (04) :823-829
[5]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[6]   Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial [J].
Calabro, Luana ;
Morra, Aldo ;
Fonsatti, Ester ;
Cutaia, Ornella ;
Amato, Giovanni ;
Giannarelli, Diana ;
Di Giacomo, Anna Maria ;
Danielli, Riccardo ;
Altomonte, Maresa ;
Mutti, Luciano ;
Maio, Michele .
LANCET ONCOLOGY, 2013, 14 (11) :1104-1111
[7]   Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma [J].
Ceresoli, GL ;
Locati, LD ;
Ferreri, AJM ;
Cozzarini, C ;
Passoni, P ;
Melloni, G ;
Zannini, P ;
Bolognesi, A ;
Villa, E .
LUNG CANCER, 2001, 34 (02) :279-287
[8]   Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation [J].
Currie, Andrew J. ;
Prosser, Amy ;
McDonnell, Alison ;
Cleaver, Amanda L. ;
Robinson, Bruce W. S. ;
Freeman, Gordon J. ;
van der Most, Robbert G. .
JOURNAL OF IMMUNOLOGY, 2009, 183 (12) :7898-7908
[9]   Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma [J].
de Perrot, Marc ;
Feld, Ronald ;
Cho, B. C. John ;
Bezjak, Andrea ;
Anraku, Masaki ;
Burkes, Ronald ;
Roberts, Heidi ;
Tsao, Ming S. ;
Leighl, Natasha ;
Keshavjee, Shaf ;
Johnston, Michael R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1413-1418
[10]   Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: The Memorial Sloan-Kettering experience [J].
Flores, RM .
LUNG CANCER, 2005, 49 :S71-S74